 OncLive | Targeted Therapies in Neuroendocrine Tumors - OncLive OncLive The hazard ratio for progression-free survival in this trial was 0.77 in favor of treatment with everolimus; however, this benefit was not statistically significant. To further cull out the benefits of everolimus in this population, the RADIANT-4 trial ... |
